Areva Pharmaceuticals launches Bupivacaine HCl Injection Covid-19 Drug shortage in the US healthcare System
Georgetown, Indiana. Areva Pharmaceuticals announced it is working with large IDN’s and hospital systems to help mitigate Bupivacaine HCL Injection shortage, USP in 0.25mg/ml, 0.5mg/ml currently in the US Healthcare System
“Areva Pharmaceuticals is very pleased to work with the US FDA and in a short time receive its temporary approval to help with the current drug shortage during the Covid 19 pandemic. This critical need drug has seen an increased demand due to the COVID-19 pandemic and Areva will be ready to meet the challenge. This approval further cements Areva’s commitment to alleviating the drug shortage crisis with sterile injectable products produced exclusively in the US market,” said Irene Swaminathan RPh, JD, MBA President and Chairwomen of Areva Pharmaceuticals.
Areva Pharmaceuticals’ Bupivacaine HCL Injection is available in cartons of 10 ampules/Pack.
About Bupivacaine HCL Injection,
Bupivacaine HCL Injection, USP is a sterile, is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia (see WARNINGS).
About Areva Pharmaceuticals Inc.
Areva Pharmaceuticals Inc., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, and more streamlined in practice for US Healthcare providers. Areva ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. Our Mission is to bring “VALUE BEYONG EACH VIAL”